4DMT Molecular Therapeutics Inc. is looking ahead to phase III as positive data continue to roll out for gene therapy candidate 4D-150 in wet age-related macular degeneration (AMD), with the results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results